Acurx Pharmaceuticals, Inc.

  • Home
  • About
    • Management / Consultants
    • Scientific / Corporate Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • Ibezapolstat
    • GPSS®
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Videos
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

ALERT: NEW ARTICLE

IDSA Clinical Infectious Diseases; Emergence and spread of Clostridioides difficile Isolates with Reduced Fidaxomicin Susceptibility in an Acute Care Hospital

Read Publication

Continue

Presentations

News & Media

News & Media

  • Press Releases
  • Presentations
  • Videos
ID Week Presentation by Dr. Michael Silverman and Dr. Kevin Garey Ibezapolstat October 2023

ID Week Presentation by Dr. Michael Silverman and Dr. Kevin Garey Ibezapolstat October 2023

ID Week Presentation Dr. Kevin Garey “Gram Positive Selective Spectrum Activity of Ibezapolstat October 2023

ID Week Presentation Dr. Kevin Garey “Gram Positive Selective Spectrum Activity of Ibezapolstat October 2023

World Antimicrobial Resistance Conference Presentation

World Antimicrobial Resistance Conference Presentation

ECCMID Presentation by Robert J. DeLuccia, Executive Chairman, Copenhagen April 2023

ECCMID Presentation by Robert J. DeLuccia, Executive Chairman, Copenhagen April 2023

Poster Presentation (ECCMID) April 2023 by Dr. Kevin Garey titled “Novel pharmacology and susceptibility of ibezapolstat against Clostridioides Difficile isolates with reduced susceptibility to C difficile directed antibiotics

Poster Presentation (ECCMID) April 2023 by Dr. Kevin Garey titled “Novel pharmacology and susceptibility of ibezapolstat against Clostridioides Difficile isolates with reduced susceptibility to C difficile directed antibiotics

ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

ID Week Presentation (October 2022) Development Update on Ibezapolstat for the Treatment of Clostridioides difficile infection: Focus on the Microbiome

Poster Presentation ID Week (October 2022) Investigating the Gram Positive Selective Spectrum of Ibezapolstat, a First in Class DNA Polymerase IIIC (Pol IIIC) Inhibitor

Poster Presentation ID Week (October 2022) Investigating the Gram Positive Selective Spectrum of Ibezapolstat, a First in Class DNA Polymerase IIIC (Pol IIIC) Inhibitor

Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS®) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

Poster Presentation and Abstract from ID Week (October 2021) titled “An Open-label Phase 2a study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS®) Antibiotic, for Patients with Clostridioides difficile Infection.” presented by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy”

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

ID Week Oral Presentation of Phase 1 Data, presented by Dr. Kevin Garey, Professor & Chair, Department of Pharmacy Practice and Translational Research, University of Houston

RSS
  • « Previous
  • 1
  • 2
  • 3
  • Next »
© 2025 Acurx Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap